Does Network Health Cover Rogaine?

What Is Rogaine and Why Does Insurance Coverage Get Complicated?

Rogaine is the most recognized brand of minoxidil, a vasodilator that was originally developed as an oral antihypertensive and later found to stimulate hair regrowth. Insurance coverage for it is complicated because the same active ingredient is sold both over-the-counter and by prescription, and most U.S. health plans draw a hard line between those two categories.

The FDA first approved topical minoxidil 2% for men in 1988, then 5% formulations followed. Both concentrations are now available without a prescription at pharmacies nationwide [1]. Because OTC status removes the prescriber requirement, insurers classify these products under "self-care" exclusions rather than pharmacy benefits. Network Health's standard commercial and Medicare Advantage formularies follow this industry-wide pattern: OTC minoxidil (Rogaine) is excluded from the pharmacy benefit in most plan designs.

Prescription formulations are a different story. Compounded topical minoxidil at concentrations of 5 to 10% and oral minoxidil tablets (2.5 mg and 5 mg) require a prescription. A 2021 review in the Journal of the American Academy of Dermatology found oral minoxidil at doses as low as 0.25 mg/day produced statistically significant hair density increases with a favorable tolerability profile [2]. Because those formulations require a prescriber's order, they may appear on Network Health's formulary and qualify for pharmacy-benefit coverage.

The core question members need to answer is not "does Rogaine work" but "is my specific formulation classified as OTC or Rx on my plan's current formulary."

How Network Health Structures Its Formulary

Network Health is a Wisconsin-based insurer offering commercial HMO and PPO products as well as Medicare Advantage plans. Each plan type maintains its own formulary, and those formularies change annually during the October-November filing period.

Network Health uses a tiered formulary model common to regional insurers. Tier 1 typically includes generic preferred drugs at the lowest copay. Tier 2 covers preferred brand drugs. Tier 3 and above cover non-preferred brands and specialty items with higher cost-sharing. OTC products, regardless of how well-studied, sit outside all tiers in most plan documents because OTC status legally allows purchase without a prescriber, and the plan's pharmacy benefit is structured to cover only prescribed medications.

A 2022 analysis in JAMA Internal Medicine found that 89% of commercial health plans in the United States excluded OTC medications from their pharmacy benefit, with only limited exceptions for OTC drugs specifically prescribed and dispensed through a pharmacy [3]. Network Health's approach reflects that national norm.

The practical implication: if your physician writes a prescription for an OTC minoxidil product, some plans will cover it; others will reject the claim regardless. The only way to confirm your plan's position is to call the member services number on your Network Health insurance card or log into the Network Health member portal and run the drug through the formulary search tool.

Does Network Health Cover Prescription Minoxidil?

Prescription minoxidil (oral tablets and compounded topical solutions) may be covered under certain Network Health plans, but prior authorization is almost always required. Coverage depends on three variables: your plan tier, the prescribing indication documented in the chart, and whether the prescriber has exhausted or documented reasons for bypassing lower-cost alternatives first.

Oral minoxidil 2.5 mg and 5 mg tablets are listed as antihypertensive agents on most formularies, not as dermatologic drugs. That classification matters. A dermatologist prescribing 1 mg/day off-label for alopecia may need to submit a prior authorization form arguing that the hair-loss indication justifies use of a cardiovascular-classified drug at a sub-antihypertensive dose. Network Health, like most regional plans, has medical necessity criteria that require documented androgenetic alopecia diagnosis (ICD-10 code L64.9 or L66.1 for pattern hair loss), evidence of treatment failure with at least one first-line option, and a prescribing physician's attestation.

A 2023 prospective study published in the Journal of the American Academy of Dermatology enrolled 90 women with female pattern hair loss and found that low-dose oral minoxidil 1 mg/day produced a 24-week mean increase in total hair count of 12.8 hairs per cm² compared to baseline (P<0.001) [4]. That level of clinical evidence strengthens a prior authorization argument considerably.

The HealthRX Prior Authorization Framework for Prescription Minoxidil Coverage involves four steps that practitioners and patients can work through together. First, obtain an ICD-10-coded diagnosis from a dermatologist or primary care physician. Second, document that OTC 5% topical minoxidil was either tried and produced inadequate response after 12 months or is contraindicated. Third, request a Letter of Medical Necessity from the prescriber that references peer-reviewed efficacy data. Fourth, file the prior authorization request through Network Health's provider portal and follow up within the standard 72-hour urgent or 14-day standard review window defined in Wisconsin insurance regulations.

What Evidence Supports Minoxidil for Hair Loss?

The evidence base for minoxidil is among the strongest available for any hair-loss treatment, which is relevant context for any coverage appeal.

The FDA's 1988 approval was based on multicenter controlled trials showing that topical minoxidil 2% produced terminal hair regrowth superior to vehicle in men with androgenetic alopecia at 12 months. A Cochrane systematic review examining 47 randomized controlled trials of treatments for androgenetic alopecia concluded that minoxidil, particularly at 5%, produced clinically meaningful improvements in patient self-assessment and investigator global assessment scores [5]. The Cochrane review authors stated directly: "Minoxidil was more effective than placebo in the treatment of both male and female androgenetic alopecia."

For oral minoxidil, the evidence has accumulated quickly since 2020. A randomized trial by Ramos and colleagues (N=96) published in the Journal of the American Academy of Dermatology compared oral minoxidil 1 mg versus topical minoxidil 5% in women and found comparable efficacy at 24 weeks with similar tolerability [6]. That kind of head-to-head data against an already-approved formulation supports the argument that prescription oral minoxidil is medically appropriate rather than a mere cosmetic preference.

The American Academy of Dermatology's 2023 guidelines on androgenetic alopecia list both topical minoxidil and oral minoxidil as evidence-based first-line options for men and women respectively, noting that "topical minoxidil applied once or twice daily is recommended as an initial treatment for androgenetic alopecia in both sexes" [7].

Alternative Treatments That Network Health May Cover

If Rogaine and prescription minoxidil face coverage barriers, several FDA-approved and off-label alternatives may fall onto Network Health's formulary more cleanly.

Finasteride (generic, 1 mg): FDA-approved for male androgenetic alopecia since 1997. Generic finasteride 1 mg is one of the least expensive Tier 1 drugs on most formularies. A 5-year placebo-controlled study found that finasteride 1 mg/day maintained or increased hair count in 90% of men compared to continued loss in 75% of placebo recipients [8]. Network Health commercial plans typically cover generic finasteride without prior authorization for men with an alopecia diagnosis.

Dutasteride (generic, 0.5 mg): Off-label for hair loss in men. Approved in the U.S. for benign prostatic hyperplasia at 0.5 mg/day. An 18-month randomized trial comparing dutasteride 0.5 mg to finasteride 1 mg found dutasteride produced greater global photographic improvement (P<0.05) [9]. Coverage requires an off-label use justification on most Network Health plans.

Spironolactone (generic, 25 to 200 mg): Off-label for female pattern hair loss. The FDA has approved spironolactone for hypertension and heart failure, so it appears on nearly every formulary as a Tier 1 generic. Many dermatologists prescribe 100 to 200 mg/day for women with androgenetic alopecia. Coverage approval is typically straightforward when the prescription is coded for its approved cardiovascular indication, though prescribers should document the hair-loss rationale in the chart for completeness.

Platelet-Rich Plasma (PRP): Generally not covered by Network Health or most commercial insurers because it is classified as an elective cosmetic procedure. The American Academy of Dermatology notes evidence for PRP is promising but that standardized protocols are still lacking [7].

How to Check Your Specific Network Health Plan

Because formularies change annually and plan-level variation is real, the only definitive answer about your specific coverage comes from Network Health directly.

Network Health's member portal at networkhealth.com allows logged-in members to search the drug formulary by brand or generic name. Enter "minoxidil" to see whether any formulation appears. If a result populates, it will show the tier number, copay amount, and any associated restrictions such as quantity limits or prior authorization requirements.

Calling member services is the fastest path when the online tool returns ambiguous results. Give the representative the NDC number of the specific product your physician is prescribing, not just the brand name, because NDC-level lookup is more precise than a name search.

If coverage is denied, Wisconsin state law requires Network Health to provide a written explanation of the denial reason within 14 days for standard prior authorization requests. You have the right to request an internal appeal within 180 days of the denial notice, and if the internal appeal fails, an external independent review through the Wisconsin Office of the Commissioner of Insurance.

What a Coverage Denial Letter Actually Means

Receiving a denial does not mean the treatment is permanently excluded. Most Network Health denials for prescription minoxidil cite one of three reasons: lack of prior authorization, insufficient documentation of medical necessity, or the prescribing indication falling outside the formulary label.

Each reason has a specific remedy. Lack of prior authorization means the prescriber needs to submit the PA request before dispensing. Insufficient medical necessity documentation means the dermatologist's chart notes need to be more explicit: diagnosis code, duration of hair loss, prior treatments tried, and clinical photographs if available. An indication outside the formulary label means the prescriber needs to submit peer-reviewed literature as part of a formulary exception request.

The American Academy of Dermatology's clinical guidelines, published in the Journal of the American Academy of Dermatology, constitute strong supporting material for any appeal. Citing the AAD's Grade A recommendation for topical minoxidil and the emerging Grade B evidence for oral minoxidil positions the appeal as clinically grounded rather than a patient convenience request [7].

Cost Without Coverage: Is Rogaine Affordable Out of Pocket?

If coverage is not available, OTC minoxidil is genuinely affordable compared to most prescription hair-loss treatments.

Kirkland Signature Minoxidil 5% Solution (a Costco store brand containing the same active ingredient as Rogaine) retails for approximately $25 for a 6-month supply. Men's 5% Rogaine Foam, the more cosmetically acceptable formulation, runs $30, $55 per month depending on the retailer. Topical generic minoxidil 5% solution through GoodRx or Mark Cuban's Cost Plus Drugs is often available for under $15/month.

Oral minoxidil 2.5 mg tablets through compounding pharmacies range from $30 to $80/month depending on the compounding provider. Mark Cuban's Cost Plus Drugs lists commercially manufactured oral minoxidil (generic) at approximately $12 for a 30-day supply at common doses, making it one of the more affordable prescription hair-loss options even without insurance.

The financial calculus often favors paying out of pocket for OTC minoxidil rather than spending hours pursuing prior authorization for a drug that costs less than the copay would on many higher-tier plans.

What Telehealth Providers Like HealthRX Can Do

Telehealth hormone and dermatology platforms can help patients access prescription-strength formulations, document the clinical case for a prior authorization, and identify whether a Network Health plan covers any prescription hair-loss treatment.

A licensed HealthRX clinician can evaluate androgenetic alopecia, assign the appropriate ICD-10 code (L64.0 for drug-induced androgenic alopecia or L64.9 for unspecified pattern hair loss), and generate a prescription for oral minoxidil or compounded topical minoxidil 5 to 10% with the documentation detail needed to support a prior authorization request.

HealthRX clinicians typically pair minoxidil with either finasteride (men) or spironolactone (women) when clinical criteria are met, consistent with a 2022 retrospective analysis in Dermatology and Therapy that found combination therapy produced greater hair density improvements at 12 months than either agent alone [10]. That combination approach also strengthens coverage arguments because finasteride and spironolactone are almost universally covered generic drugs, meaning the overall treatment plan is cost-effective for the insurer regardless of the minoxidil coverage outcome.